The ex vivo investigations involving human T-cells and pure TDEVs unequivocally associate TDEVs with the decline of CD8+ T-cells noted in cancer patients, particularly pronounced following immunotherapy, during which CD8+ T-cells are stimulated and susceptible to apoptosis (217, 218). This evidence concerns the gene CD8A and cancer.